» Articles » PMID: 39329996

Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2024 Sep 27
PMID 39329996
Authors
Affiliations
Soon will be listed here.
Abstract

Ranked high in worldwide growing health issues, pleural diseases affect approximately one million people globally per year and are often correlated with a poor prognosis. Among these pleural diseases, malignant pleural mesothelioma (PM), a neoplastic disease mainly due to asbestos exposure, still remains a diagnostic challenge. Timely diagnosis is imperative to define the most suitable therapeutic approach for the patient, but the choice of diagnostic modalities depends on operator experience and local facilities while bearing in mind the yield of each diagnostic procedure. Since the analysis of pleural fluid cytology is not sufficient in differentiating historical features in PM, histopathological and morphological features obtained via tissue biopsies are fundamental. The quality of biopsy samples is crucial and often requires highly qualified expertise. Since adequate tissue biopsy is essential, medical or video-assisted thoracoscopy (MT or VATS) is proposed as the most suitable approach, with the former being a physician-led procedure. Indeed, MT is the diagnostic gold standard for malignant pleural pathologies. Moreover, this medical or surgical approach can allow diagnostic and therapeutic procedures: it provides the possibility of video-assisted biopsies, the drainage of high volumes of pleural fluid and the administration of sterile calibrated talcum powder under visual control in order to achieve pleurodesis, placement of indwelling pleural catheters if required and in a near future potential intrapleural therapy. In this context, dedicated diagnostic pathways remain a crucial need, especially to quickly and properly diagnose PM. Lastly, the interdisciplinary approach and multidisciplinary collaboration should always be implemented in order to direct the patient to the best customised diagnostic and therapeutic pathway. At the present time, the diagnosis of PM remains an unsolved problem despite MDT (multidisciplinary team) meetings, mainly because of the lack of standardised diagnostic work-up. This review aims to provide an overview of diagnostic procedures in order to propose a clear strategy.

Citing Articles

Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.

Andretta E, Costa A, Ventura E, Quintiliani M, Damiano S, Giordano A Nutrients. 2024; 16(21).

PMID: 39519591 PMC: 11547426. DOI: 10.3390/nu16213758.

References
1.
Hassan R, Remaley A, Sampson M, Zhang J, Cox D, Pingpank J . Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006; 12(2):447-53. DOI: 10.1158/1078-0432.CCR-05-1477. View

2.
Qureshi N, Gleeson F . Imaging of pleural disease. Clin Chest Med. 2006; 27(2):193-213. DOI: 10.1016/j.ccm.2006.02.001. View

3.
Sato T, Sekido Y . NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. Int J Mol Sci. 2018; 19(4). PMC: 5979333. DOI: 10.3390/ijms19040988. View

4.
Grigoriu B, Chahine B, Vachani A, Gey T, Conti M, Sterman D . Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med. 2009; 179(10):950-4. DOI: 10.1164/rccm.200807-1125OC. View

5.
Conway R, Smith N, Cooper W, Lynch G, Patole S, Symonds J . Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort. ERJ Open Res. 2024; 9(6). PMC: 10763666. DOI: 10.1183/23120541.00467-2023. View